Michael K. Bamat

1.0k total citations
21 papers, 814 citations indexed

About

Michael K. Bamat is a scholar working on Oncology, Genetics and Epidemiology. According to data from OpenAlex, Michael K. Bamat has authored 21 papers receiving a total of 814 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Genetics and 5 papers in Epidemiology. Recurrent topics in Michael K. Bamat's work include Colorectal Cancer Treatments and Studies (12 papers), Virus-based gene therapy research (8 papers) and Pancreatic and Hepatic Oncology Research (7 papers). Michael K. Bamat is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Virus-based gene therapy research (8 papers) and Pancreatic and Hepatic Oncology Research (7 papers). Michael K. Bamat collaborates with scholars based in United States and Canada. Michael K. Bamat's co-authors include Robert M. Lorence, William S. Groene, M. Scot Roberts, John L. Marshall, Daniel H. Sterman, Gary I. Cohen, Harvey Rabin, Andrew L. Pecora, Peter Groß and Stuart L. Goldberg and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Michael K. Bamat

20 papers receiving 791 citations

Peers

Michael K. Bamat
Ursula Bantel‐Schaal Germany
Laurent Deleu Germany
László K. Csatáry United States
Emily V. Mesev United States
Oya Cingöz United States
Emmanouela Linardakis United States
T S Ranheim United States
Cuizhu Zhang China
Christie Bell United States
Roman Žák United States
Ursula Bantel‐Schaal Germany
Michael K. Bamat
Citations per year, relative to Michael K. Bamat Michael K. Bamat (= 1×) peers Ursula Bantel‐Schaal

Countries citing papers authored by Michael K. Bamat

Since Specialization
Citations

This map shows the geographic impact of Michael K. Bamat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael K. Bamat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael K. Bamat more than expected).

Fields of papers citing papers by Michael K. Bamat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael K. Bamat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael K. Bamat. The network helps show where Michael K. Bamat may publish in the future.

Co-authorship network of co-authors of Michael K. Bamat

This figure shows the co-authorship network connecting the top 25 collaborators of Michael K. Bamat. A scholar is included among the top collaborators of Michael K. Bamat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael K. Bamat. Michael K. Bamat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Garcia, Rolando A.G., Joel A. Saydoff, Michael K. Bamat, & Reid W. von Borstel. (2018). Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency. Toxicology and Applied Pharmacology. 353. 67–73. 2 indexed citations
2.
Saydoff, Joel A., et al.. (2016). Uridine triacetate as an effective antidote in preclinical models of 5-FU overdoses and impaired 5-FU clearance.. Journal of Clinical Oncology. 34(15_suppl). e18232–e18232.
3.
Wee, Wen, Muhammad Wasif Saif, Bassel F. El‐Rayes, et al.. (2016). Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity. Cancer. 123(2). 345–356. 84 indexed citations
4.
Wee, Wen, Bassel F. El‐Rayes, Marwan Fakih, et al.. (2016). Clinical trial experience with uridine triacetate for 5-fluorouracil toxicity.. Journal of Clinical Oncology. 34(4_suppl). 655–655. 3 indexed citations
5.
Wee, Wen, Thomas H. Cartwright, Bassel F. El‐Rayes, et al.. (2016). Uridine triacetate as a life-saving antidote to capecitabine toxicity.. Journal of Clinical Oncology. 34(15_suppl). e21612–e21612. 1 indexed citations
6.
Bamat, Michael K., et al.. (2013). Clinical Experience with Uridine Triacetate for 5-Fluorouracil Overexposure: an Update. Annals of Oncology. 24. iv71–iv71. 4 indexed citations
7.
White, Jason, et al.. (2011). Point-of-care (POC) diagnostic assay for 5-fluorouracil (5-FU) quantitation to enable dose adjustment and detect dihydropyrimidine dehydrogenase (DPD) deficiency.. Journal of Clinical Oncology. 29(15_suppl). e19562–e19562. 3 indexed citations
8.
Bamat, Michael K., et al.. (2011). Uridine triacetate for prevention of 5FU toxicity due to dihydropyrimidine dehydrogenase (DPD) deficiency.. Journal of Clinical Oncology. 29(15_suppl). e19560–e19560. 2 indexed citations
9.
Bamat, Michael K., et al.. (2010). Uridine triacetate: An orally administered, life-saving antidote for 5-FU overdose.. Journal of Clinical Oncology. 28(15_suppl). 9084–9084. 9 indexed citations
10.
Saydoff, Joel A., et al.. (2010). Uridine triacetate for lethal 5-FU toxicity due to dihydropyrimidine dehydrogenase (DPD) deficiency.. Journal of Clinical Oncology. 28(15_suppl). e13505–e13505. 9 indexed citations
11.
Bamat, Michael K., et al.. (2009). Vistonuridine: An orally administered, life-saving antidote for 5-fluorouracil (5FU) overdose. Journal of Clinical Oncology. 27(15_suppl). 9616–9616. 5 indexed citations
12.
Lorence, Robert M., M. Scot Roberts, James P. O’Neil, et al.. (2007). Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus. Current Cancer Drug Targets. 7(2). 157–167. 93 indexed citations
13.
Hotte, Sébastien J., Robert M. Lorence, Hal W. Hirte, et al.. (2007). An Optimized Clinical Regimen for the Oncolytic Virus PV701. Clinical Cancer Research. 13(3). 977–985. 98 indexed citations
14.
Laurie, Scott A., John C. Bell, Harold Atkins, et al.. (2006). A Phase 1 Clinical Study of Intravenous Administration of PV701, an Oncolytic Virus, Using Two-Step Desensitization. Clinical Cancer Research. 12(8). 2555–2562. 103 indexed citations
15.
Lorence, Robert M., et al.. (2006). Naturally oncolytic viruses.. PubMed. 8(4). 314–21. 45 indexed citations
16.
Hotte, Sébastien J., Pierre Major, Holger W. Hirte, et al.. (2004). Slow intravenous infusion of PV701, an oncolytic virus: Final results of a phase I study. Journal of Clinical Oncology. 22(14_suppl). 3037–3037. 4 indexed citations
17.
Hotte, Sébastien J., Pierre Major, Holger W. Hirte, et al.. (2004). Slow intravenous infusion of PV701, an oncolytic virus: Final results of a phase I study. Journal of Clinical Oncology. 22(14_suppl). 3037–3037. 1 indexed citations
18.
Pecora, Andrew L., Naiyer A. Rizvi, Gary I. Cohen, et al.. (2002). Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers. Journal of Clinical Oncology. 20(9). 2251–2266. 314 indexed citations
19.
Lorence, Robert M., Andrew L. Pecora, Gary I. Cohen, et al.. (2001). An intravenous phase I trial of PV701, a replication-competent virus, in the treatment of patients with advanced solid cancers. European Journal of Cancer. 37. S65–S65. 5 indexed citations
20.
Nelson, Randy J., Michael K. Bamat, & Irving Zucker. (1982). Photoperiodic Regulation of Testis Function in Rats: Mediation by a Circadian Mechanism. Biology of Reproduction. 26(2). 329–335. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ursula Bantel‐Schaal Breakdown of academic impact, for papers by Laurent Deleu Breakdown of academic impact, for papers by László K. Csatáry Breakdown of academic impact, for papers by Emily V. Mesev Breakdown of academic impact, for papers by Oya Cingöz Breakdown of academic impact, for papers by Emmanouela Linardakis Breakdown of academic impact, for papers by T S Ranheim Breakdown of academic impact, for papers by Cuizhu Zhang Breakdown of academic impact, for papers by Christie Bell Breakdown of academic impact, for papers by Roman Žák
Rankless by CCL
2026